Tag: NIH
-
Biotech Start-Up Finds STD Treatment in Anti-Cancer Therapy
Researchers with the biotechnology company TherapyX Inc. in Buffalo, New York found a potential treatment for the sexually transmitted disease (STD) gonorrhea in a therapy the company is developing for cancer. The team from TherapyX, a spin-off company of the University at Buffalo medical school, published its findings today online in the Journal of Infectious…
-
Portal Launched Matching Cancer Cells to Drug Molecules
The Broad Institute, a medical research organization with scientists from Harvard University and Massachusetts Institute of Technology, opened its Cancer Therapeutics Response Portal, an online resource that matches potential drug molecules to their sensitivities among hundreds of cancer cell lines. The portal is described this week in the journal Cell (paid subscription required), in an…
-
NIH Funding Micro-Sutures for Stem Cell Heart Muscle Repair
Researchers at Worcester Polytechnic Institute in Massachusetts and University of Washington in Seattle are collaborating on development of tiny bio-compatible polymer threads that help stem cells repair damaged heart muscle. The work of Worcester Tech biomedical engineers Glenn Gaudette and George Pins, with Washington pathology professor Michael Laflamme is funded by a five-year $1.94 million…
-
Early Human Trial Tests Ultrasound to Heal Venous Ulcers
Biomedical engineers at Drexel University in Philadelphia designed an ultrasound device, which early tests show can speed healing of venous skin ulcers that are normally slow to heal. The team led by engineering professor Peter Lewin expects to publish its findings later this month in the Journal of the Acoustical Society of America. Venous skin…
-
Biotech Gets Small Business Funds for Universal Flu Vaccine
TechnoVax Inc., a biotechnology company in Tarrytown, New York, received a grant from National Institute of Allergy and Infectious Diseases, part of National Institutes of Health, to develop a vaccine that protects against a wide assortment of flu strains. The initial award of $300,000, made under the Small Business Innovation Research (SBIR) program at NIH,…
-
NIH Funds Three New Neurologic Drug Discovery Projects
National Institutes of Health is funding three new neurological drug research initiatives to address Fragile X syndrome, nicotine addiction, and age-related macular degeneration. Awards for the three projects, from the National Institute of Neurological Disorders and Stroke (NINDS), total nearly $446,000. The three studies are funded under the Neurotherapeutics Network, part of the NIH Blueprint…
-
TB Diagnostics Developer Gains $1.5M in Early Financing
TB Biosciences, a biotechnology company in Bethlehem, Pennsylvania developing genomics-based diagnostics for tuberculosis, received $1.5 million in its first fund-raising round after initial start-up. The financing was led by Bethlehem venture capital company Originate Ventures, joined by Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. Tuberculosis, or TB, is a…
-
Cancer Genetic Variations Database Generated for Therapies
Researchers at National Cancer Institute (NCI), part of National Institutes of Health, cataloged the genetic variations of nine leading types of cancers, and are making the data available to the cancer research community. The team led by pharmacologist Yves Pommier and geneticist Paul Meltzer posted its findings today online in the journal Cancer Research (paid…
-
Research Funded for DNA Vaccine to Create Nicotine Immunity
Researchers at Arizona State University in Tempe are investigating the ability of human DNA, assembled into nanoscale particles, to help people develop an immunity to nicotine. The project is funded by a three-year $3.3 million grant from National Institute of Drug Abuse, part of National Institutes of Health, and led by Arizona State immunologist Yung…
-
Pharmas, Academics Partner on New Treatments from Old Drugs
Researchers from pharmaceutical companies and academic labs are partnering on finding therapies for eight types of diseases from drugs tested to treat other disorders. The $12.7 million pilot program, led by National Center for Advancing Translational Sciences (NCATS), part of National Institutes of Health, funds nine separate projects combining industry and university scientists for up…